Mesothelin Antibody (G-4): sc-166125

Mesothelin Antibody (G-4) is a mouse monoclonal IgG2b antibody that detects mesothelin in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Mesothelin is a glycosylphosphatidylinositol-linked cell-surface molecule predominantly expressed in the mesothelial lining of body cavities and is notably overexpressed in various tumor cells, making mesothelin a significant tumor antigen in human ovarian cancers and mesotheliomas. Mesothelin plays a crucial role in cell adhesion and signaling, which is vital for maintaining tissue integrity and facilitating cellular communication. Aberrant mesothelin expression in tumors not only aids in cancer progression but also serves as a potential biomarker for diagnosis and therapeutic targeting. Mesothelin immunoreactivity is particularly pronounced in serous papillary, endometrioid, and undifferentiated ovarian cancers, as well as pancreatic cancers, while less frequent staining is observed in adenocarcinomas of the endometrium, lung, and stomach/esophagus. In adult mouse tissues, mesothelin transcript is found in the lung, heart, spleen, liver, kidney, and testis, highlighting mesothelin′s diverse biological roles and potential implications in both normal physiology and disease states. Anti-mesothelin antibody (G-4) is an essential tool for researchers investigating mesothelin function and pathology in various contexts.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Mesothelin Antibody (G-4) References:

1. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.  |  O'Hara, M., et al. 2016. Immunotherapy. 8: 449-60. PMID: 26973126
2. Clinical impacts of mesothelin expression in gastrointestinal carcinomas.  |  Einama, T., et al. 2016. World J Gastrointest Pathophysiol. 7: 218-22. PMID: 27190694
3. Periostin and mesothelin: Potential predictors of malignant progression in intrahepatic cholangiocarcinoma.  |  Mandrekar, P. and Cardinale, V. 2018. Hepatol Commun. 2: 481-483. PMID: 29761164
4. Targeting mesothelin in ovarian cancer.  |  Ghafoor, A., et al. 2018. Oncotarget. 9: 36050-36051. PMID: 30546824
5. Immunotherapy targeting mesothelin in acute myeloid leukemia.  |  Wang, Q. and Gong, R. 2022. J Leukoc Biol. 112: 813-821. PMID: 35946307
6. The Role of Mesothelin in Activation of Portal Fibroblasts in Cholestatic Liver Injury.  |  Nishio, T., et al. 2022. Biology (Basel). 11: PMID: 36358290
7. ZFP36 disruption is insufficient to enhance the function of mesothelin-targeting human CAR-T cells.  |  Mai, D., et al. 2024. Sci Rep. 14: 3113. PMID: 38326511
8. Structural elucidation of the mesothelin-mucin-16/CA125 interaction.  |  Rupert, PB., et al. 2024. Structure. 32: 1049-1054.e2. PMID: 38703776
9. Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer.  |  Torchiaro, E., et al. 2024. J Transl Med. 22: 1100. PMID: 39627822

The preferred Mesothelin antibody is Mesothelin Antibody (K1): sc-33672.